Figure 3
From: The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms
Panels a (H&E) and b (PAX5) show a case of CHL with weak PAX5 reactivity. This case was CD30-positive and CD15-positive, but also expressed CD3. Panels c (H&E) and d (PAX5) feature a case of NLPHL that showed moderate PAX5 expression and the following immunophenotype: CD30-negative, CD20-weak positive, CD15-negative and epithelial membrane antigen-negative (original magnification × 200).
